VolitionRx shows biomarker-driven lung cancer insights at NACLC 2025

VolitionRx Limited, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q^® Cancer assays in the management of lung cancer patients.

Prognostic Value of Circulating H3K27Me3-Nucleosomes in Newly Diagnosed Lung Cancer Patients

Professor Lea Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon and Hospices Civils de Lyon, France, said:

“This large-scale study demonstrates that Nu.Q^®-H3K27Me3 levels increase with cancer disease stages and importantly, that their level at diagnosis emerges as an independent prognostic biomarker for overall survival. It offers a practical approach to refine risk assessment, particularly within the ctDNA-negative subgroup and to inform clinical decision-making in the context of personalized therapeutic strategies.

“We have worked closely with the Volition team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q^® in the management of cancer patients.

“We were delighted to place our first order of the Nu.Q^® Cancer assays recently so we might complete the internal certification process ahead of introducing the test into routine clinical practice in our hospital network for cancer management.”

Pre-operative nucleosome liquid biopsy for risk stratification of lung cancer

Joint lead author Dr. Pei-Hsing Chen, Institute of Biomedical Engineering, National Taiwan University (NTU), Taipei City, Taiwan, said:
“A key finding from this study was that measuring preoperative H3K27Me3-nucleosomes using Volition’s simple blood test allows us to identify which Non Small Cell Lung Cancer patients are most likely to benefit from closer follow-ups or secondary cancer treatment.

“While high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes, low H3K27me3 levels indicated significantly better outcomes. High H3K27Me3-nucleosome levels may also flag micro-metastatic disease, guiding systemic-therapy decisions in high-risk patients.

“The Nu.Q^® Cancer technology supports a practical approach to empower clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey.”

Dr Andrew Retter, Chief Medical Officer of Volition, said:

“Nu.Q^® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring.

“Research conducted by our long-term collaborators in Lyon and Taiwan consistently demonstrates that our Nu.Q^® Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey.

“By enriching clinical prognostication, Nu.Q^® Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care.